CoChat

Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: On the basis of reductions in diabetic kidney disease (DKD) progression and major adverse cardiovascular events observed in the landmark CREDENCE trial, canagliflozin 100 mg received an extension to its EU marketing authorisation in July 2020 to include the treatment of DKD in people with type 2 diabetes mellitus (T2DM) making it the first pharmacological therapy to receive regulatory authorisation for treatment of DKD since the RENAAL and IDNT trials in nearly 20 years. Efficient allocation of limited healthcare resources requires evaluation not only of clinical safety and efficacy but also economic consequences. The study aim was to estimate the cost-effectiveness of canagliflozin when added to current standard of care (SoC) versus SoC alone from the perspective of the NHS in England. METHODS: A microsimulation model was developed using patient-level data from CREDENCE, including risk equations for the key clinical outcomes of start of dialysis, hospitalisation for heart failure, nonfatal myocardial infarction, nonfatal stroke, and all-cause mortality. DKD progression was modelled using estimated glomerular filtration rate and urinary albumin-to-creatinine ratio evolution equations. Risk for kidney transplant was sourced from UK-specific sources given the near absence of events in CREDENCE. Patient characteristics and treatment effects were sourced from CREDENCE. Unit costs (£2019) and disutility weights were sourced from the literature and discounted at 3.5% annually. The time horizon was 10 years in the base case, and sensitivity analysis was performed. RESULTS: Canagliflozin was associated with sizable gains in life-years and quality-adjusted life-year (QALYs) over 10 years, with gains increasing with simulation duration. Cost offsets associated with reductions in cardiovascular and renal complications were sufficient to achieve overall net cost savings. The findings were generally confirmed in the sensitivity analyses. CONCLUSION: Model results suggest that adding canagliflozin 100 mg to SoC can improve patient outcomes while reducing overall net costs from the NHS perspective in England. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02065791.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-020-00968-x

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CREDEM-DKD model structure. *Optionally, doubling of serum creatinine can also be simulated. AE adverse event, CVD cardiovascular disease, CREDEM-DKD CREDENCE Economic Model of DKD, CREDENCE Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation, DoSCr doubling of serum creatinine, eGFR estimated glomerular filtration rate, HF heart failure, HHF hospitalization for heart failure, Hx history, ICER incremental cost-effectiveness ratio, MI myocardial infarction, LY life-year, QALY quality-adjusted life-year, RRT renal replacement therapy, UACR urine albumin-to-creatinine ratio
Fig. 1 CREDEM-DKD model structure. *Optionally, doubling of serum creatinine can also be simulated. AE adverse event, CVD cardiovascular disease, CREDEM-DKD CREDENCE Economic Model of DKD, CREDENCE Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation, DoSCr doubling of serum creatinine, eGFR estimated glomerular filtration rate, HF heart failure, HHF hospitalization for heart failure, Hx history, ICER incremental cost-effectiveness ratio, MI myocardial infarction, LY life-year, QALY quality-adjusted life-year, RRT renal replacement therapy, UACR urine albumin-to-creatinine ratioCC BY-NC · PubMed Central
Fig. 2 Progression of DKD stages over time. RRT renal replacement therapy
Fig. 2 Progression of DKD stages over time. RRT renal replacement therapyCC BY-NC · PubMed Central
Fig. 3 Cumulative incidence of renal and CV outcomes, by study arm. HHF hospitalization for heart failure, MI myocardial infarction
Fig. 3 Cumulative incidence of renal and CV outcomes, by study arm. HHF hospitalization for heart failure, MI myocardial infarctionCC BY-NC · PubMed Central
Fig. 4 Cost-effectiveness scatter plot of canagliflozin 100 mg + SoC versus SoC alone
Fig. 4 Cost-effectiveness scatter plot of canagliflozin 100 mg + SoC versus SoC aloneCC BY-NC · PubMed Central
Fig. 5 Cost-effectiveness acceptability curve of canagliflozin 100 mg + SoC versus SoC alone
Fig. 5 Cost-effectiveness acceptability curve of canagliflozin 100 mg + SoC versus SoC aloneCC BY-NC · PubMed Central
Fig. 6 Estimated total costs, total QALYs, and NMBs, by scenario. * Willingness-to-pay of £30,000 per QALY. eGFR estimated glomerular filtration rate, HR hazard ratio, NMB net monetary benefit, QALY quality adjusted life-years
Fig. 6 Estimated total costs, total QALYs, and NMBs, by scenario. * Willingness-to-pay of £30,000 per QALY. eGFR estimated glomerular filtration rate, HR hazard ratio, NMB net monetary benefit, QALY quality adjusted life-yearsCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 36

Metadata

Authors
Willis, M., Nilsson, A., Kellerborg, K., Ball, P., Roe, R., Traina, S., Beale, R., & Newell, I.
Affiliations
  • Swedish Institute for Health Economics (SE)
  • Mundipharma (United Kingdom) (GB)
  • Napp Pharmaceuticals (United Kingdom) (GB)
  • Costello Medical Consulting (United Kingdom) (GB)
Corresponding author
Willis, Michael
Venue
Diabetes Therapy
Published
2020-12-02
Volume
12
Issue
1
Pages
313-328
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W3109444236
Cited by
36
References
37
Citations by year
2026: 3 · 2025: 2 · 2024: 11 · 2023: 3 · 2022: 10 · 2021: 6 · 2020: 1
FWCI
4.25
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
canagliflozin, diabetic nephropathy, type 2 diabetes, cost-effectiveness, SGLT2 inhibitors, CREDENCE trial, microsimulation model, quality-adjusted life years, dialysis, cardiovascular events, kidney transplantation, healthcare resource allocation, NHS England

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model. https://app.cochat.ai/papers/10.1007/s13300-020-00968-x
The paper
Willis, M., Nilsson, A., Kellerborg, K., Ball, P., Roe, R., Traina, S., Beale, R., & Newell, I. (2021). Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model. Diabetes Therapy. https://doi.org/10.1007/s13300-020-00968-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.